Clinical Trial Update: Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pyrotinib with trastuzumab and an aromatase inhibitor for HER2-positive breast cancer showing ongoing status with no final results disc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Fuzhou General Hospital | Conditions: Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN